Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomeAnnouncementsAnnouncement Detail

Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions

May 16, 2017 – The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on menopausal hormone therapy for the primary prevention of chronic conditions. Based on its review of the evidence, the Task Force recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. This is a D recommendation. The Task Force also recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had their uterus removed. This is a D recommendation. The draft recommendation statement and draft evidence review are available for review and public comment from May 16, 2017 to June 12, 2017 at http://www.uspreventiveservicestaskforce.org/Page/Name/us-preventive-services-task-force-opportunities-for-public-comment.

Current as of: May 2017

Internet Citation: Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions. U.S. Preventive Services Task Force. May 2017.
https://www.uspreventiveservicestaskforce.org/Announcements/News/Item/menopausal-hormone-therapy-for-the-primary-prevention-of-chronic-conditions

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857